株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の幹細胞医薬品の提携契約の動向

Global Stem Cell Partnering 2010-2017: Deal Trends, Players, Financials and Forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 355309
出版日 ページ情報 英文 370 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
世界の幹細胞医薬品の提携契約の動向 Global Stem Cell Partnering 2010-2017: Deal Trends, Players, Financials and Forecasts
出版日: 2017年10月04日 ページ情報: 英文 370 Pages
概要

当レポートでは、幹細胞医薬品に関連する各種提携契約の動向について調査し、近年締結された各種契約の動向、大規模契約および大手事業者による契約の概要、契約区分・開発ステージ・治療分野・技術タイプ別の一覧などをまとめています。

第1章 イントロダクション

第2章 幹細胞医薬品関連契約の動向

  • イントロダクション
  • 過去数年の提携動向
  • 提携契約にもっとも活発な事業者
  • 提携契約:契約区分別
  • 提携契約:治療分野別
  • 提携契約の条件
    • 取引総額
    • 契約一時金
    • マイルストーンペイメント
    • ロイヤルティレート

第3章 主要契約

  • イントロダクション
  • 主要契約:契約額別

第4章 提携契約にもっとも活発な事業者

  • イントロダクション
  • 提携契約にもっとも活発な事業者
  • 提携契約にもっとも活発な事業者のプロファイル

第5章 提携契約ディレクトリー

  • イントロダクション
  • 提携契約ディレクトリー

第6章 幹細胞医薬品関連契約:技術区分別

第7章 提携契約リソースセンター

  • オンラインよる提携
  • 提携イベント
  • 提携契約関連資料

付録1:提携契約 - 企業別 (A-Z)

付録2:提携契約 - 開発ステージ別

  • 創薬
  • 前臨床
  • 第I相
  • 第II相
  • 第III相
  • 申請段階
  • 上市済み
  • 調剤段階

付録3:提携契約 - タイプ別

  • 資産購入
  • 譲渡
  • バイオ医薬品アウトライセンシング
  • 共同開発
  • 共同R&D
  • 共同販売
  • 共同プロモーション
  • CRADA
  • クロスライセンシング
  • 開発
  • 流通販売
  • 株式購入
  • 評価
  • 助成
  • ジョイントベンチャー
  • ライセンシング
  • 訴訟
  • 製造
  • マーケティング
  • 物質移動
  • オプション
  • プロモーション
  • 研究
  • 合意
  • スピンアウト
  • サブライセンス
  • 供給
  • 技術移転
  • 契約解除
  • 保証

付録4:提携契約 - 治療分野別

付録5 -提携区分の定義

Wildwood Venturesについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2117

The Global Stem Cell Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in stem cell partnering
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for stem cells

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 500 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Stem Cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Key benefits

Global Stem Cell Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Stem Cell deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Stem Cell agreements with numerous real life case studies
  • Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
  • Identify most active Stem Cell dealmakers since 2010
  • Insight into terms included in a Stem Cell partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Stem Cell Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.

Stem Cell Partnering Terms and Agreements includes:

  • Trends in Stem Cell dealmaking in the biopharma industry since 2010
  • Analysis of Stem Cell deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Stem Cell deals
  • Access to Stem Cell contract documents
  • Leading Stem Cell deals by value since 2010
  • Most active Stem Cell dealmakers since 2010

In Global Stem Cell Partnering 2010-2017: Deal trends, players, financials and forecasts , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Stem Cell Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 500 Stem Cell deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefitss

Global Stem Cell Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of stem cell deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of stem cell agreements with numerous real life case studies
  • Detailed access to actual stem cell contracts entered into by leading biopharma companies
  • Identify most active stem cell dealmakers since 2010
  • Insight into terms included in a stem cell partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking

  • 2.1. Introduction
  • 2.2. Stem Cell partnering over the years
  • 2.3. Most active Stem Cell dealmakers
  • 2.4. Stem Cell partnering by deal type
  • 2.5. Stem Cell partnering by therapy area
  • 2.6. Deal terms for Stem Cell partnering
    • 2.6.1 Stem Cell partnering headline values
    • 2.6.2 Stem Cell deal upfront payments7
    • 2.6.3 Stem Cell deal milestone payments
    • 2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals

  • 3.1. Introduction
  • 3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers

  • 4.1. Introduction
  • 4.2. Most active Stem Cell dealmakers
  • 4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Stem Cell deals by company A-Z

Appendix 2 - Stem Cell deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Stem Cell deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Stem Cell deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Stem Cell partnering since 2010
  • Figure 2: Active Stem Cell dealmaking activity since 2010
  • Figure 3: Stem Cell partnering by deal type since 2010
  • Figure 4: Stem Cell partnering by disease type since 2010
  • Figure 5: Stem Cell deals with a headline value
  • Figure 6: Stem Cell deals with an upfront value
  • Figure 7: Stem Cell deals with a milestone value
  • Figure 8: Stem Cell deals with a royalty rate value
  • Figure 9: Top Stem Cell deals by value since 2010
  • Figure 10: Most active Stem Cell dealmakers since 2010
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top